BiotechTube

mRNA-1608

Phase 2Completed
0 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Genital Herpes

Conditions

Genital Herpes

Trial Timeline

Sep 6, 2023 → Apr 25, 2025

NCT ID
NCT06033261

About mRNA-1608

mRNA-1608 is a phase 2 stage product being developed by Moderna for Genital Herpes. The current trial status is completed. This product is registered under clinical trial identifier NCT06033261. Target conditions include Genital Herpes.

What happened to similar drugs?

10 of 20 similar drugs in Genital Herpes were approved

Approved (10) Terminated (0) Active (10)
✅Risankizumab + Placebo for RisankizumabAbbVieApproved
✅Famciclovir + PlaceboNovartisApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved
✅activated recombinant human factor VIINovo NordiskApproved

Clinical Trials (1)

NCT IDPhaseStatus
NCT06033261Phase 2Completed

Competing Products

20 competing products in Genital Herpes

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
Fulvestrant + AbemaciclibEli LillyPhase 2
39
EDIT-101Editas MedicinePhase 1/2
18
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
ASP2151 + PlaceboAstellas PharmaPhase 1
29
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Topical NO + PlaceboKyowa KirinPhase 2
35
KW-3357Kyowa KirinPhase 1
29
Ixekizumab + PlaceboEli LillyPhase 3
40
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
40
DaratumumabJohnson & JohnsonPhase 2
27
Risankizumab + Placebo for RisankizumabAbbVieApproved
43